BHVN

10.44

3.16% 0.32

Vorhandelsmarkt: 10.46 0.02 +0.19%

Biohaven Ltd (BHVN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BHVN? Forum Prognose

Schlusskurs vom Vortag:

$10.12

Offen:

$10.3

24-Stunden-Volumen:

1.59M

Relative Volume:

0.65

Marktkapitalisierung:

$1.57B

Einnahmen:

Nettoeinkommen (Verlust:

$-738.82M

KGV:

-1.50

EPS:

-6.9602

Netto-Cashflow:

$-610.15M

1W Leistung:

+12.74%

1M Leistung:

+8.98%

6M Leistung:

-37.33%

1J Leistung:

-43.60%

1-Tages-Spanne:

$10.23

$10.80

1-Wochen-Bereich:

$9.04

$10.80

52-Wochen-Spanne:

$7.48

$24.06

Biohaven Ltd Stock (BHVN) Company Profile

Firmenname

Biohaven Ltd

Sektor

Healthcare (1110)

Branche

Biotechnology (622)

Telefon

203-404-0410

Adresse

215 CHURCH STREET, NEW HAVEN, CT

Mitarbeiter

274

Twitter

@biohavenpharma

Nächster Verdiensttermin

2025-08-08

Neueste SEC-Einreichungen

BHVN's Discussions on Twitter

Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BHVN Biohaven Ltd	10.44	1.38B	0	-738.82M	-610.15M	-6.9602
VRTX Vertex Pharmaceuticals Inc	444.28	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	755.51	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	828.35	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	339.41	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	310.00	34.37B	5.36B	287.73M	924.18M	2.5229

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-06	Eingeleitet	Goldman	Buy
2026-01-21	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2025-12-03	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-11-26	Herabstufung	UBS	Buy → Neutral
2025-11-06	Herabstufung	Bernstein	Outperform → Mkt Perform
2025-11-05	Herabstufung	BofA Securities	Buy → Neutral
2025-09-17	Eingeleitet	Citigroup	Buy
2025-09-03	Eingeleitet	Raymond James	Strong Buy
2025-05-19	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-09-16	Eingeleitet	Jefferies	Buy
2024-09-04	Eingeleitet	Bernstein	Outperform
2024-07-24	Eingeleitet	Morgan Stanley	Overweight
2024-02-16	Eingeleitet	RBC Capital Mkts	Outperform
2024-02-06	Eingeleitet	UBS	Buy
2023-12-22	Eingeleitet	H.C. Wainwright	Buy
2023-12-08	Eingeleitet	Robert W. Baird	Outperform
2023-01-24	Eingeleitet	SVB Securities	Outperform
2023-01-04	Eingeleitet	JP Morgan	Overweight
2022-12-02	Eingeleitet	BTIG Research	Buy
2022-10-26	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2022-10-12	Eingeleitet	Piper Sandler	Overweight
2022-08-19	Herabstufung	Piper Sandler	Overweight → Neutral
2022-08-08	Herabstufung	Wedbush	Outperform → Neutral
2022-05-11	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-10-19	Fortgesetzt	Morgan Stanley	Equal-Weight
2021-08-10	Herabstufung	UBS	Buy → Neutral
2021-08-03	Bestätigt	Canaccord Genuity	Buy
2021-03-11	Eingeleitet	UBS	Buy
2020-12-15	Eingeleitet	H.C. Wainwright	Buy
2020-04-17	Eingeleitet	Cowen	Outperform
2020-02-10	Herabstufung	Oppenheimer	Outperform → Perform
2020-02-06	Eingeleitet	Mizuho	Buy
2019-11-22	Eingeleitet	Wedbush	Outperform
2019-06-25	Bestätigt	Canaccord Genuity	Buy
2019-05-06	Eingeleitet	Goldman	Buy
2019-04-09	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2019-03-04	Bestätigt	Needham	Buy
2018-07-03	Bestätigt	Needham	Buy
2018-07-02	Bestätigt	Needham	Buy
2018-04-05	Herabstufung	Barclays	Overweight → Equal Weight
2018-02-22	Bestätigt	Canaccord Genuity	Buy
2017-12-15	Eingeleitet	Canaccord Genuity	Buy
2017-10-03	Bestätigt	Needham	Buy

Alle ansehen

Biohaven Ltd Aktie (BHVN) Neueste Nachrichten

Apr 14, 2026

Biohaven (BHVN) fuels confidence with encouraging azetukalner data - MSN

Apr 14, 2026

Apr 13, 2026

Why Institutions Are Turning Bullish on Biohaven—and the Catalyst That Could Unlock Its Value - NAI500

Apr 13, 2026

Why Biohaven Stock Crushed it on Monday - Yahoo Finance

Apr 13, 2026

FOMO Trade: What is the implied volatility of Biohaven LtdMarket Performance Recap & Real-Time Buy Signal Notifications - baoquankhu1.vn

Apr 13, 2026

CCORF Initiates Biohaven(BHVN.US) With Buy Rating, Announces Target Price $21 - Moomoo

Apr 13, 2026

Biohaven’s BHV-1450 shows promise for pemphigus vulgaris - BioWorld News

Apr 13, 2026

Hedge Fund Bets: How does Biohaven Ltd score in quality rankings2026 Big Picture & Safe Capital Allocation Plans - baoquankhu1.vn

Apr 13, 2026

Whale Trades: How does Biohaven Ltd score in quality rankingsWeekly Risk Summary & High Yield Stock Recommendations - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Here is why Biohaven (BHVN) is Among the Top Healthcare Stocks Insiders Are Buying - Insider Monkey

Apr 12, 2026

8 Healthcare Stocks Insiders Are Buying - Insider Monkey

Apr 12, 2026

Apr 11, 2026

Decliners Report: Is Biohaven Ltd showing insider buyingMarket Movers & Consistent Income Trade Recommendations - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Entry Recap: Is Biohaven Ltd showing insider buyingMarket Volume Report & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Apr 10, 2026

Apr 08, 2026

Earnings Update: What is the long term forecast for Biohaven Ltd stock2026 Trends & Technical Pattern Based Signals - baoquankhu1.vn

Apr 08, 2026

Aug Spikes: What is the long term forecast for Biohaven Ltd stock2026 Update & Consistent Profit Trade Alerts - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

BHVN PE Ratio & Valuation, Is BHVN Overvalued - Intellectia AI

Apr 04, 2026

BHVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

Apr 03, 2026

Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart

Apr 03, 2026

Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial - Sahm

Apr 03, 2026

Apr 02, 2026